Our primary research interest and focus is to explore dynamic co-evolution between tumor cells and tumor microenvironment during tumor development, drug resistance and metastasis using cutting-edge and integrative experimental approaches. We will explore critical molecular mechanisms and will rationally design and test novel strategies to overcome the drug resistance and metastasis by using novel combinatorial immunotherapy. The ultimate goal of our research is to translate the mechanistic findings into clinically tangible treatment regimens to benefit cancer patients. One of our recent research focuses is to dissect and modulate myelopoiesis for effective therapy in triple-negative breast cancer. By using syngeneic animal models coupled with multi-modal single-cell approaches, we aim to track the evolving path of tumor associated myeloid populations and to uncover the molecular underpinnings of myeloid cells reprogramming that instate immunosuppression and tumor promoting activities. We hope to provide insights into novel breast cancer treatment strategies by modulating specific myeloid subtypes that will deliver better clinical outcomes.
Ph.D. - School of Medicine, Shanghai Jiaotong University, Shanghai, China 07/2012
